GSK, Angiochem to develop drugs for lysosomal disease symptoms

02/27/2012 | Reuters

GlaxoSmithKline and Angiochem agreed to develop treatments intended to relieve neurological symptoms related to lysosomal storage diseases. Angiochem could get more than $300 million, including as much as $31.5 million upfront, plus sales royalties.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA